APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acinetobacter Infections Treatment

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

Selected research

Market Analysis & Forecast

Global Acinetobacter Infections Treatment Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchAcinetobacter Infections Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Acinetobacter Infections Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Acinetobacter Infections Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acinetobacter Infections Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Acinetobacter Infections Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

Read the full market overview

In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.

Report Includes

This report presents an overview of global market for Acinetobacter Infections Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acinetobacter Infections Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Acinetobacter Infections Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acinetobacter Infections Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acinetobacter Infections Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acinetobacter Infections Treatment revenue, projected growth trends, production technology, application and end-user industry.

Acinetobacter Infections Treatment Segment by Company

Entasis Therapeutics

Roche

Adenium Biotech

Vaxdyn

Hsiri Therapeutics

Aridis Pharmaceuticals

LegoChem Biosciences

Atterx Biotherapeutics

Achaogen

Peptilogics

Sealife PHARMA

Shionogi

Techulon

Tetraphase Pharmaceuticals

Acinetobacter Infections Treatment Segment by Type

Sulbactam

Carbapenems

Aminoglycosides

Polymyxins

Tetracyclines

Others

Acinetobacter Infections Treatment Segment by Pipeline

ETX2514

Nacubactam RG6080

Arenicin

VXD-001

Small Molecule Antibiotic

AR-401 mAB

LCB01-0371 (PO)

GN-4474

Antibacterial Antibody

Others

Acinetobacter Infections Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acinetobacter Infections Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acinetobacter Infections Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acinetobacter Infections Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acinetobacter Infections Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Sulbactam Major Player Table 3. Carbapenems Major Player Table 4. Aminoglycosides Major Player Table 5. Polymyxins Major Player Table 6. Tetracyclines Major Player Table 7. Others Major Player Table 8. Global Acinetobacter Infections Treatment Market Size Growth Rate by Pipeline (US$ Million), 2021 VS 2025 VS 2032 Table 9. ETX2514 Major Player Table 10. Nacubactam RG6080 Major Player Table 11. Arenicin Major Player Table 12. VXD-001 Major Player Table 13. Small Molecule Antibiotic Major Player Table 14. AR-401 mAB Major Player Table 15. LCB01-0371 (PO) Major Player Table 16. GN-4474 Major Player Table 17. Antibacterial Antibody Major Player Table 18. Others Major Player Table 19. Acinetobacter Infections Treatment Industry Trends Table 20. Acinetobacter Infections Treatment Industry Drivers Table 21. Acinetobacter Infections Treatment Industry Opportunities and Challenges Table 22. Acinetobacter Infections Treatment Industry Restraints Table 23. Global Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 24. Global Acinetobacter Infections Treatment Market Size by Region (2021-2026) & (US$ Million) Table 25. Global Acinetobacter Infections Treatment Market Share by Region (2021-2026) Table 26. Global Acinetobacter Infections Treatment Market Size by Region (2027-2032) & (US$ Million) Table 27. Global Acinetobacter Infections Treatment Market Share by Region (2027-2032) Table 28. Global Acinetobacter Infections Treatment Revenue by Players (US$ Million) & (2021-2026) Table 29. Global Acinetobacter Infections Treatment Revenue Market Share by Players (2021-2026) Table 30. Global Acinetobacter Infections Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 31. Global Acinetobacter Infections Treatment Key Players Headquarters & Area Served Table 32. Global Acinetobacter Infections Treatment Players, Product Type & Application Table 33. Global Acinetobacter Infections Treatment Players Establishment Date Table 34. Global Players Market Concentration Ratio (CR5 and HHI) Table 35. Global Acinetobacter Infections Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Acinetobacter Infections Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2021-2026) Table 40. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2027-2032) Table 41. Global Acinetobacter Infections Treatment Revenue by Pipeline 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 43. Global Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 44. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2021-2026) Table 45. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2027-2032) Table 46. Entasis Therapeutics Company Information Table 47. Entasis Therapeutics Business Overview Table 48. Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio Table 50. Entasis Therapeutics Recent Development Table 51. Roche Company Information Table 52. Roche Business Overview Table 53. Roche Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Roche Acinetobacter Infections Treatment Product Portfolio Table 55. Roche Recent Development Table 56. Adenium Biotech Company Information Table 57. Adenium Biotech Business Overview Table 58. Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Adenium Biotech Acinetobacter Infections Treatment Product Portfolio Table 60. Adenium Biotech Recent Development Table 61. Vaxdyn Company Information Table 62. Vaxdyn Business Overview Table 63. Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Vaxdyn Acinetobacter Infections Treatment Product Portfolio Table 65. Vaxdyn Recent Development Table 66. Hsiri Therapeutics Company Information Table 67. Hsiri Therapeutics Business Overview Table 68. Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio Table 70. Hsiri Therapeutics Recent Development Table 71. Aridis Pharmaceuticals Company Information Table 72. Aridis Pharmaceuticals Business Overview Table 73. Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio Table 75. Aridis Pharmaceuticals Recent Development Table 76. LegoChem Biosciences Company Information Table 77. LegoChem Biosciences Business Overview Table 78. LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio Table 80. LegoChem Biosciences Recent Development Table 81. Atterx Biotherapeutics Company Information Table 82. Atterx Biotherapeutics Business Overview Table 83. Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio Table 85. Atterx Biotherapeutics Recent Development Table 86. Achaogen Company Information Table 87. Achaogen Business Overview Table 88. Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Achaogen Acinetobacter Infections Treatment Product Portfolio Table 90. Achaogen Recent Development Table 91. Peptilogics Company Information Table 92. Peptilogics Business Overview Table 93. Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Peptilogics Acinetobacter Infections Treatment Product Portfolio Table 95. Peptilogics Recent Development Table 96. Sealife PHARMA Company Information Table 97. Sealife PHARMA Business Overview Table 98. Sealife PHARMA Acinetobacter Infections Treatment Sales (Cases), Revenue (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 99. Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio Table 100. Sealife PHARMA Recent Development Table 101. Shionogi Company Information Table 102. Shionogi Business Overview Table 103. Shionogi Acinetobacter Infections Treatment Sales (Cases), Revenue (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 104. Shionogi Acinetobacter Infections Treatment Product Portfolio Table 105. Shionogi Recent Development Table 106. Techulon Company Information Table 107. Techulon Business Overview Table 108. Techulon Acinetobacter Infections Treatment Sales (Cases), Revenue (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 109. Techulon Acinetobacter Infections Treatment Product Portfolio Table 110. Techulon Recent Development Table 111. Tetraphase Pharmaceuticals Company Information Table 112. Tetraphase Pharmaceuticals Business Overview Table 113. Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Sales (Cases), Revenue (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 114. Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio Table 115. Tetraphase Pharmaceuticals Recent Development Table 116. North America Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 119. North America Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 120. North America Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Acinetobacter Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Acinetobacter Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 126. Europe Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 127. Europe Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Acinetobacter Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Acinetobacter Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 130. China Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 131. China Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 132. China Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 133. China Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 134. Asia Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 137. Asia Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 138. Asia Acinetobacter Infections Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Acinetobacter Infections Treatment Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Acinetobacter Infections Treatment Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Acinetobacter Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Acinetobacter Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026) & (US$ Million) Table 144. SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032) & (US$ Million) Table 145. SAMEA Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Acinetobacter Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Acinetobacter Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Acinetobacter Infections Treatment Image Figure 2. Global Acinetobacter Infections Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acinetobacter Infections Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Sulbactam Image Figure 5. Carbapenems Image Figure 6. Aminoglycosides Image Figure 7. Polymyxins Image Figure 8. Tetracyclines Image Figure 9. Others Image Figure 10. Global Acinetobacter Infections Treatment Market Size Growth Rate by Pipeline (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Acinetobacter Infections Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 12. ETX2514 Image Figure 13. Nacubactam RG6080 Image Figure 14. Arenicin Image Figure 15. VXD-001 Image Figure 16. Small Molecule Antibiotic Image Figure 17. AR-401 mAB Image Figure 18. LCB01-0371 (PO) Image Figure 19. GN-4474 Image Figure 20. Antibacterial Antibody Image Figure 21. Others Image Figure 22. Global Acinetobacter Infections Treatment Market Size (US$ Million) & (2021-2032) Figure 23. Global Acinetobacter Infections Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 24. Global Acinetobacter Infections Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 25. Global Acinetobacter Infections Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Acinetobacter Infections Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Acinetobacter Infections Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2021-2032) Figure 30. Global Acinetobacter Infections Treatment Revenue by Pipeline (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2021 VS 2025 VS 2032) Figure 32. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2021-2032) Figure 33. North America Acinetobacter Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. North America Acinetobacter Infections Treatment Revenue Share by Type (2021-2032) Figure 35. North America Acinetobacter Infections Treatment Revenue Share by Application (2021-2032) Figure 36. North America Acinetobacter Infections Treatment Revenue Share by Country (2021-2032) Figure 37. United States Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Canada Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Mexico Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Europe Acinetobacter Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. Europe Acinetobacter Infections Treatment Revenue Share by Type (2021-2032) Figure 42. Europe Acinetobacter Infections Treatment Revenue Share by Application (2021-2032) Figure 43. Europe Acinetobacter Infections Treatment Revenue Share by Country (2021-2032) Figure 44. Germany Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. France Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. U.K. Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Italy Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. Spain Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. Russia Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Netherlands Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Nordic Countries Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. China Acinetobacter Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 53. China Acinetobacter Infections Treatment Revenue Share by Type (2021-2032) Figure 54. China Acinetobacter Infections Treatment Revenue Share by Application (2021-2032) Figure 55. Asia Acinetobacter Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. Asia Acinetobacter Infections Treatment Revenue Share by Type (2021-2032) Figure 57. Asia Acinetobacter Infections Treatment Revenue Share by Application (2021-2032) Figure 58. Asia Acinetobacter Infections Treatment Revenue Share by Region (2021-2032) Figure 59. Japan Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. South Korea Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. India Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Australia Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Taiwan Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Southeast Asia Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. SAMEA Acinetobacter Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 66. SAMEA Acinetobacter Infections Treatment Revenue Share by Type (2021-2032) Figure 67. SAMEA Acinetobacter Infections Treatment Revenue Share by Application (2021-2032) Figure 68. SAMEA Acinetobacter Infections Treatment Revenue Share by Country (2021-2032) Figure 69. Brazil Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Argentina Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Chile Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Colombia Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Peru Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Saudi Arabia Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Israel Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. UAE Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 77. Turkey Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 78. Iran Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 79. Egypt Acinetobacter Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 80. Years Considered Figure 81. Research Process Figure 82. Key Executives Interviewed

Scope & coverage.

Types
  • Sulbactam
  • Carbapenems
  • Aminoglycosides
  • Polymyxins
  • Tetracyclines
  • Others
Applications
  • ETX2514
  • Nacubactam RG6080
  • Arenicin
  • VXD-001
  • Small Molecule Antibiotic
  • AR-401 mAB
  • LCB01-0371 (PO)
  • GN-4474
  • Antibacterial Antibody
  • Others
Companies covered
  • Entasis Therapeutics
  • Roche
  • Adenium Biotech
  • Vaxdyn
  • Hsiri Therapeutics
  • Aridis Pharmaceuticals
  • LegoChem Biosciences
  • Atterx Biotherapeutics
  • Achaogen
  • Peptilogics
  • Sealife PHARMA
  • Shionogi
  • Techulon
  • Tetraphase Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acinetobacter Infections Treatment Market by Type
  3. 1.2.1 Global Acinetobacter Infections Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Sulbactam
  5. 1.2.3 Carbapenems
  6. 1.2.4 Aminoglycosides
  7. 1.2.5 Polymyxins
  8. 1.2.6 Tetracyclines
  9. 1.2.7 Others
  10. 1.3 Acinetobacter Infections Treatment Market by Pipeline
  11. 1.3.1 Global Acinetobacter Infections Treatment Market Size by Pipeline, 2021 VS 2025 VS 2032
  12. 1.3.2 ETX2514
  13. 1.3.3 Nacubactam RG6080
  14. 1.3.4 Arenicin
  15. 1.3.5 VXD-001
  16. 1.3.6 Small Molecule Antibiotic
  17. 1.3.7 AR-401 mAB
  18. 1.3.8 LCB01-0371 (PO)
  19. 1.3.9 GN-4474
  20. 1.3.10 Antibacterial Antibody
  21. 1.3.11 Others
  22. 1.4 Assumptions and Limitations
  23. 1.5 Study Goals and Objectives
2 Acinetobacter Infections Treatment Market Dynamics
  1. 2.1 Acinetobacter Infections Treatment Industry Trends
  2. 2.2 Acinetobacter Infections Treatment Industry Drivers
  3. 2.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges
  4. 2.4 Acinetobacter Infections Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acinetobacter Infections Treatment Market Perspective (2021-2032)
  2. 3.2 Global Acinetobacter Infections Treatment Growth Trends by Region
  3. 3.2.1 Global Acinetobacter Infections Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acinetobacter Infections Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Acinetobacter Infections Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acinetobacter Infections Treatment Revenue by Players
  2. 4.1.1 Global Acinetobacter Infections Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acinetobacter Infections Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acinetobacter Infections Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acinetobacter Infections Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Acinetobacter Infections Treatment Players, Product Type & Application
  8. 4.5 Global Acinetobacter Infections Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acinetobacter Infections Treatment Market CR5 and HHI
  11. 4.6.3 2025 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier 3
5 Acinetobacter Infections Treatment Market Size by Type
  1. 5.1 Global Acinetobacter Infections Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Acinetobacter Infections Treatment Revenue Market Share by Type (2021-2032)
6 Acinetobacter Infections Treatment Market Size by Application
  1. 6.1 Global Acinetobacter Infections Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acinetobacter Infections Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Acinetobacter Infections Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Entasis Therapeutics
  2. 7.1.1 Entasis Therapeutics Company Information
  3. 7.1.2 Entasis Therapeutics Business Overview
  4. 7.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio
  6. 7.1.5 Entasis Therapeutics Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Acinetobacter Infections Treatment Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Adenium Biotech
  14. 7.3.1 Adenium Biotech Company Information
  15. 7.3.2 Adenium Biotech Business Overview
  16. 7.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio
  18. 7.3.5 Adenium Biotech Recent Developments
  19. 7.4 Vaxdyn
  20. 7.4.1 Vaxdyn Company Information
  21. 7.4.2 Vaxdyn Business Overview
  22. 7.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio
  24. 7.4.5 Vaxdyn Recent Developments
  25. 7.5 Hsiri Therapeutics
  26. 7.5.1 Hsiri Therapeutics Company Information
  27. 7.5.2 Hsiri Therapeutics Business Overview
  28. 7.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
  30. 7.5.5 Hsiri Therapeutics Recent Developments
  31. 7.6 Aridis Pharmaceuticals
  32. 7.6.1 Aridis Pharmaceuticals Company Information
  33. 7.6.2 Aridis Pharmaceuticals Business Overview
  34. 7.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
  36. 7.6.5 Aridis Pharmaceuticals Recent Developments
  37. 7.7 LegoChem Biosciences
  38. 7.7.1 LegoChem Biosciences Company Information
  39. 7.7.2 LegoChem Biosciences Business Overview
  40. 7.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
  42. 7.7.5 LegoChem Biosciences Recent Developments
  43. 7.8 Atterx Biotherapeutics
  44. 7.8.1 Atterx Biotherapeutics Company Information
  45. 7.8.2 Atterx Biotherapeutics Business Overview
  46. 7.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
  48. 7.8.5 Atterx Biotherapeutics Recent Developments
  49. 7.9 Achaogen
  50. 7.9.1 Achaogen Company Information
  51. 7.9.2 Achaogen Business Overview
  52. 7.9.3 Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
  54. 7.9.5 Achaogen Recent Developments
  55. 7.10 Peptilogics
  56. 7.10.1 Peptilogics Company Information
  57. 7.10.2 Peptilogics Business Overview
  58. 7.10.3 Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
  60. 7.10.5 Peptilogics Recent Developments
  61. 7.11 Sealife PHARMA
  62. 7.11.1 Sealife PHARMA Company Information
  63. 7.11.2 Sealife PHARMA Business Overview
  64. 7.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
  66. 7.11.5 Sealife PHARMA Recent Developments
  67. 7.12 Shionogi
  68. 7.12.1 Shionogi Company Information
  69. 7.12.2 Shionogi Business Overview
  70. 7.12.3 Shionogi Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
  72. 7.12.5 Shionogi Recent Developments
  73. 7.13 Techulon
  74. 7.13.1 Techulon Company Information
  75. 7.13.2 Techulon Business Overview
  76. 7.13.3 Techulon Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
  78. 7.13.5 Techulon Recent Developments
  79. 7.14 Tetraphase Pharmaceuticals
  80. 7.14.1 Tetraphase Pharmaceuticals Company Information
  81. 7.14.2 Tetraphase Pharmaceuticals Business Overview
  82. 7.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
  84. 7.14.5 Tetraphase Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Acinetobacter Infections Treatment Revenue (2021-2032)
  2. 8.2 North America Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Acinetobacter Infections Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Acinetobacter Infections Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
  7. 8.4.1 North America Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
  8. 8.4.2 North America Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
  9. 8.5 North America Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
  10. 8.6 North America Acinetobacter Infections Treatment Revenue by Country
  11. 8.6.1 North America Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acinetobacter Infections Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Acinetobacter Infections Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Acinetobacter Infections Treatment Revenue (2021-2032)
  2. 9.2 Europe Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acinetobacter Infections Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acinetobacter Infections Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
  7. 9.4.1 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
  8. 9.4.2 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
  9. 9.5 Europe Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
  10. 9.6 Europe Acinetobacter Infections Treatment Revenue by Country
  11. 9.6.1 Europe Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acinetobacter Infections Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acinetobacter Infections Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Acinetobacter Infections Treatment Revenue (2021-2032)
  2. 10.2 China Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Acinetobacter Infections Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Acinetobacter Infections Treatment Revenue by Type (2027-2032)
  5. 10.3 China Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
  7. 10.4.1 China Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
  8. 10.4.2 China Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
  9. 10.5 China Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acinetobacter Infections Treatment Revenue (2021-2032)
  2. 11.2 Asia Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acinetobacter Infections Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acinetobacter Infections Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
  7. 11.4.1 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
  8. 11.4.2 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
  9. 11.5 Asia Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
  10. 11.6 Asia Acinetobacter Infections Treatment Revenue by Country
  11. 11.6.1 Asia Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acinetobacter Infections Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acinetobacter Infections Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acinetobacter Infections Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Acinetobacter Infections Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acinetobacter Infections Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acinetobacter Infections Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
  7. 12.4.1 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
  8. 12.4.2 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
  9. 12.5 SAMEA Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
  10. 12.6 SAMEA Acinetobacter Infections Treatment Revenue by Country
  11. 12.6.1 SAMEA Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acinetobacter Infections Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acinetobacter Infections Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst